| Autor: |
R, Erber, A, Hartmann, M W, Beckmann, A, Mackensen, A, Kremer, H, Reimann, H, Hübner, A, Hein, M P, Lux, S, Jud, L, Häberle, P, Gaß, B, Volz, R, Schulz-Wendtland, M, Rübner, P A, Fasching |
| Jazyk: |
němčina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Der Pathologe. 39(Suppl 2) |
| ISSN: |
1432-1963 |
| Popis: |
The interaction of our immune system with breast cancer (BC) cells prompted the investigation of tumor-infiltrating lymphocytes (TILs) and targeted, tumor antigen-specific immunotherapy.Correlation between TILs and pathological complete response (pCR) after neoadjuvant systemic therapy (NACT). Tumor-specific antigens (TSAs) in HER2+ and triple negative BC and establishment of TSA-specific therapies within the interdisciplinary TILGen study.Illustration of the TILGen study design. Assessment of TILs and correlation with pCR within this BC study.pCR was achieved in 38.4% (56/146) and associated with estrogen receptor/progesterone receptor negative (ER-/PR-) and HER2+ tumors. Lymphocytic predominant BC (LPBC) was found in 16.4% (24/146), particularly in ER-/PR- (ER-: 27.3% vs. ER+: 9.9%, PR-: 22.3% vs. PR+: 8.2%), large, and poorly differentiated BC. TILs were significantly correlated with pCR in multivariate analysis. In LPBC, pCR was achieved in 66.7%, whereas it was 32.8% in non-LPBC.First results confirm the influence of the human immune system on the response to NACT in HER2+ and triple negative BC. TSA-specific immunotherapy might improve the outcome in BC patients but there is an urgent need for comprehensive studies to further investigate this issue. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink